department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Palsonify · pharmadog

pharmadog
drugs
Palsonify

drug · small molecule

patient view →

paltusotine hydrochloride

Marketedupdated 2mo ago

by $CRNX Crinetics Pharmaceuticals, Inc.🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Unknown (across all indications), with 3 investigational indications.

all catalysts(1)

approval · 1

PALSONIFY (PALTUSOTINE HYDROCHLORIDE) — FDA approval

paltusotine hydrochloride

News(0)

no news has mentioned this drug yet

brand

Palsonify

generic

paltusotine hydrochloride

MOA

12.1 Mechanism of Action Similar to the natural hormone somatostatin, paltusotine suppresses growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion. Paltusotine exerts its pharmacological activity via selective agonism (>4000-fold) at somatostatin receptor 2 (SSTR2) and exhibits little or no affinity for other SST receptor subtypes. Paltusotine inhibited cyclic adenosine monophosphate accumulation via human SSTR2 activation with an average drug (agonist) concentration that results in half-maximal response (EC 50 ) of 0.25 nM.

indication

Carcinoid Syndrome (Malignant Carcinoid Syndrome)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 15m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$CRNX42.03-0.47%

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 25, 2030

~4.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

Mar 25, 2044method-of-use (U-4282)US 12208092
Mar 25, 2044method-of-use (U-4282)US 12208092
Sep 7, 2041formulationUS 11266641
Sep 7, 2041formulationUS 11266641
Sep 7, 2041method-of-use (U-4283)US 11957674
Sep 7, 2041method-of-use (U-4283)US 11957674
Jan 16, 2039compositionUS 10464918
Jan 16, 2039compositionUS 10464918
Jul 12, 2037compositionUS 10351547
Jul 12, 2037compositionUS 10351547
Jul 12, 2037compositionUS 10597377
Jul 12, 2037compositionUS 10597377
Jul 12, 2037method-of-use (U-4283)US 10875839
Jul 12, 2037method-of-use (U-4283)US 10875839
Jul 12, 2037compositionUS 11414397
Jul 12, 2037compositionUS 11414397
Jul 12, 2037compositionUS 9896432
Jul 12, 2037compositionUS 9896432

FDA exclusivities (2)

Sep 25, 2030NCENew Chemical Entity (5y)4.2y
Sep 25, 2030NCENew Chemical Entity (5y)4.2y

🐶 often sniffed alongside

top 3

tagApproval4 co-mentions · 1 sources
drugPALSONIFY4 co-mentions · 1 sources
tagSmall Molecule2 co-mentions · 1 sources